GSK Pharmaceuticals India vs Sanofi India: Share Price, Comparison and Key Differences

August 12, 2026
Posted by: Kunal Singla
Category: News

GSK Pharmaceuticals India MCap approx Rs 35,000 Cr (data approximate). Sanofi India MCap Rs 7,705 Cr, PE 23.79x, ROE 39.20%, D/E 0.02, Div 3.67%.

GSK Pharmaceuticals India vs Sanofi India is a comparison MNC pharma investors look up when evaluating two listed Indian subsidiaries of global pharmaceutical multinationals. GSK Pharmaceuticals India (now Haleon spin-off discussions aside – it sells prescription medicines including Augmentin, Calpol and vaccines), a Mumbai-based company, is the Indian subsidiary of GlaxoSmithKline (GSK) in the ethical pharma division. Sanofi India, a Mumbai-based company, is the Indian subsidiary of Sanofi S.A. (France) selling prescription medicines including Clexane (blood thinner), Toujeo (insulin), Amaryl (diabetes) and other products. Both GSK Pharmaceuticals India vs Sanofi India are MNC branded pharma subsidiaries listed on Indian exchanges.

This GSK Pharmaceuticals India vs Sanofi India article covers reach and market position, key products, latest declared results and stock valuation. All data is sourced from Groww and public company filings.

Table of Contents

Reach and Market Position

In this GSK Pharmaceuticals India vs Sanofi India comparison, GSK Pharmaceuticals India sells prescription antibiotics, vaccines, respiratory and consumer healthcare products including Augmentin, Calpol and Panadol across India. Market capitalisation is approximately Rs 35,000 Cr.

Click Here – Get Free Investment Predictions

Sanofi India sells prescription cardiovascular, diabetes, thrombosis and CNS medicines including Clexane, Amaryl, Toujeo and Allegra. Market capitalisation is Rs 7,705 Cr.

Key Products and Business Mix

For the GSK Pharmaceuticals India vs Sanofi India product breakdown, GSK Pharmaceuticals India: GSK Pharmaceuticals India earns from prescription antibiotic and branded medicines. Data is approximate – investors should verify current financials from GSK Pharmaceuticals India’s exchange filings.

Sanofi India: Sanofi India earns from cardiovascular, diabetes and anti-infective prescription medicines. EPS is Rs 140.60. PE is 23.79x (cheap for MNC pharma!), ROE 39.20 percent (excellent!), D/E 0.02. Dividend yield is 3.67 percent – very high.

Latest Results and Financial Data

On the GSK Pharmaceuticals India vs Sanofi India results front: GSK Pharmaceuticals India has a market cap of approximately Rs 35,000 Cr. GSK Pharma India is one of the largest MNC pharma companies listed in India. Investors should verify current financials from exchange filings.

Sanofi India has a market cap of Rs 7,705 Cr and PE of 23.79x. ROE is 39.20 percent – exceptional for a pharma company. The dividend yield of 3.67 percent is very high for an MNC pharma subsidiary.

Compare GSK Pharmaceuticals India and Sanofi India Fundamentals on the Univest Screener

Stock Performance and Valuation

Investors tracking the GSK Pharmaceuticals India vs Sanofi India comparison should verify current prices on NSE or BSE before trading. The GSK Pharmaceuticals India vs Sanofi India stock data below reflects the latest available figures from Groww and public company filings.

GSK Pharmaceuticals India vs Sanofi India at current valuations: GSK Pharma India has approximately Rs 35,000 Cr market cap. Sanofi India trades at Rs 7,705 Cr market cap, PE 23.79x, ROE 39.20 percent, Div 3.67 percent. Sanofi India is dramatically cheaper on PE with higher verifiable ROE and exceptional dividend yield.

GSK Pharmaceuticals India vs Sanofi India: Quick Comparison Table

The comparison table below summarises the key metrics side by side.

Parameter	GSK Pharmaceuticals India	Sanofi India
Sector	Prescription antibiotics + vaccines + respiratory (GSK, UK)	Cardiovascular + diabetes + anti-infective (Sanofi, France)
Market Cap	Approx Rs 35,000 Cr	Rs 7,705 Cr
P/E Ratio	Approx (verify from filings)	23.79x
ROE	Approx (verify from filings)	39.20% (excellent)
Key Products	Augmentin, Calpol, Panadol, vaccines	Clexane, Amaryl, Toujeo, Allegra
Parent	GlaxoSmithKline (UK)	Sanofi S.A. (France)
Dividend Yield	Varies (verify from filings)	3.67% (very high)

Conclusion

The GSK Pharmaceuticals India vs Sanofi India comparison above covers reach, products, results and valuation. GSK Pharmaceuticals India vs Sanofi India covers two MNC branded pharma subsidiaries with contrasting financial profiles. GSK Pharma India is the larger company with a broader product portfolio. Sanofi India has demonstrated exceptional ROE and a very high dividend yield at a reasonable PE. GSK vs Sanofi investors should track branded prescription medicine market share and their respective parent companies’ India priorities. Consult a SEBI-registered advisor for personalised guidance.

Download the Univest iOS App or Univest Android App to track GSK Pharmaceuticals India and Sanofi India live price and get daily stock recommendations.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions

What does GSK Pharmaceuticals India sell?

Ans. GSK Pharmaceuticals India sells prescription branded medicines including Augmentin (amoxicillin-clavulanate antibiotic), Calpol (paracetamol), Panadol, Ceftum and several vaccines.

What does Sanofi India sell?

Ans. Sanofi India sells prescription branded medicines in India including Clexane (enoxaparin sodium for blood clots), Amaryl (glimepiride for diabetes), Toujeo (insulin), Dupixent (biologic) and Allegra (fexofenadine for allergy).

Why is Sanofi India dividend yield so high?

Ans. Sanofi India’s dividend yield of 3.67 percent reflects its capital-efficient model (no manufacturing capex, only marketing and distribution) and parent company policy of returning cash to shareholders.

Are GSK Pharma India and Sanofi India in Nifty 50?

Ans. Neither is in Nifty 50. Both are tracked in smaller indices.

What is branded pharma?

Ans. Branded pharma involves selling medicines under proprietary brand names at premium prices, as opposed to generic medicines. MNC pharma subsidiaries like GSK and Sanofi typically sell branded versions of their patented and off-patent molecules.

Which is larger, GSK Pharma India or Sanofi India?

Ans. GSK Pharmaceuticals India at approximately Rs 35,000 Cr is approximately 4.5 times larger than Sanofi India at Rs 7,705 Cr.

Does Sanofi India pay dividends?

Ans. Yes. Sanofi India pays a very high dividend yield of approximately 3.67 percent – one of the highest in the Indian pharma sector.

News

Author: Kunal Singla

Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.